Perioperative intravenous lidocaine for the prevention of chronic postsurgical pain: a systematic review and meta-analysis of randomized controlled trials
- Journal
- Frontiers in medicine (Q1)
- Published
- 28 September 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Wei-Jing Zhu, Ran An, Qian-Yun Pang, Xiao-Long Liang
- PMID
- 42865434
- DOI
- 10.3389/fmed.2026.1927770
Why clinicians should know about it
- Picked for Anesthesiology and Pain Medicine (paper of the day, 15 October 2026): IV lidocaine for prevention of chronic postsurgical pain meta‑analysis
Abstract
BACKGROUND: Chronic postsurgical pain (CPSP) poses a significant clinical burden, yet the efficacy of perioperative intravenous lidocaine for its prevention remains inconclusive. This meta-analysis evaluates its preventive efficacy and administration regimens. METHODS: PubMed, EMBASE, and the Cochrane Library were searched from database inception to a prespecified cutoff of June 1, 2025; final electronic searches were run on June 8, 2025, to identify randomized controlled trials (RCTs) comparing perioperative intravenous lidocaine with placebo/standard care in adults. Primary outcomes were CPSP incidence at 3 and 6 months postoperatively. RESULTS: Eighteen RCTs (1,391 patients) were included. Intravenous lidocaine significantly reduced CPSP incidence (RR = 0.67; 95% CI: 0.53 to 0.85; P = 0.001) and neuropathic pain risk (RR = 0.60; 95% CI: 0.43 to 0.85; P = 0.004) at 3 months. However, the reduction in the incidence of CPSP was not statistically significant at 6 months (RR = 0.68; 95% CI: 0.41 to 1.12; P = 0.13). Exploratory subgroup analyses of CPSP incidence at 3 months showed favorable pooled estimates in selected surgery and administration-regimen categories; however, they did not demonstrate a statistically significant difference between regimen categories. Safety assessment was limited by inconsistent adverse-event reporting and limited pharmacokinetic monitoring. CONCLUSION: Perioperative intravenous lidocaine reduces CPSP at 3 months, but evidence of an effect on CPSP incidence at 6 months remains inconclusive. Future trials should incorporate structured pharmacokinetic monitoring and exposure-response analyses and evaluate lidocaine's additive value alongside optimal regional anesthesia. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, https://www.crd.york.ac.uk/PROSPERO/view/CRD420251063756, identifier CRD420251063756.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.